RLMD — RELMADA THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1553643 ·
Last close
$7.17
Market Cap
$752.06M
52W High
$8.00
52W Low
$4.23
ADV30
1,158,269
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -19,461,754 | -19,051,956 | 235,362,794 | 9,776,400 | 16,630,217 |
| Dec 2025 | 0 | — | -20,333,112 | -19,867,760 | 94,003,471 | 3,496,540 | 7,491,458 |
| Sep 2025 | 0 | — | -10,327,346 | -10,091,496 | 14,876,244 | 1,384,484 | 5,410,705 |
| Jun 2025 | 0 | — | -10,221,306 | -9,866,442 | 21,116,144 | 1,353,351 | 5,166,663 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-45,786,988
Investing CF
$-48,138,306
Financing CF
$93,564,808
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.90
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-698,267,198
Inventory
—
Receivables
—
ST Investments
$89,509,710
EBIT TTM
$-59,100,199
Pretax Income TTM
$-57,385,163
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -59,100,200 | -57,385,163 | 94,003,471 | 7,491,458 | — | -45,786,988 |
| Dec 2024 | 0 | -83,891,036 | -79,979,354 | 45,817,818 | 10,295,857 | — | -51,755,798 |
| Dec 2023 | 0 | -103,702,293 | -98,791,746 | 97,552,042 | 12,194,800 | — | -51,659,206 |
| Dec 2022 | 0 | -161,249,076 | -157,043,823 | 152,905,179 | 12,468,877 | — | -103,801,617 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.41
Max Pain — expiry 2026-06-18
max pain strike: $5.00 · spot: $7.17 · call oi: 3,547 · put oi: 507
Expected Move to 2026-06-18:
±$1.30
(18.13%) —
implied range
$5.87 –
$8.47
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ANRO | Alto Neuroscience, Inc. | $739.08M | $21.06 | — |
| BIOA | BioAge Labs, Inc. | $720.13M | $16.20 | — |
| DSGN | Design Therapeutics, Inc. | $712.01M | $11.40 | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $709.59M | $33.68 | — |
| ESPR | Esperion Therapeutics, Inc. | $803.19M | $3.12 | — |
News headlines (Yahoo Finance, 1h cache)
Relmada Therapeutics Inc (RLMD) Q1 2026 Earnings Call Highlights: Strong Financial Position and ...
2026-05-13 05:02 · Yahoo
Relmada Therapeutics Q1 Earnings Call Highlights
2026-05-13 02:06 · Yahoo
Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-12 20:05 · Yahoo
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
2026-05-06 11:00 · Yahoo
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026
2026-05-05 11:00 · Yahoo
Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?
2026-04-13 13:55 · Yahoo
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
2026-04-06 15:10 · Yahoo
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
2026-04-02 14:00 · Yahoo
Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know
2026-03-26 13:55 · Yahoo
Here’s What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) Stock
2026-03-25 05:34 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.